| Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark. | |
| | |
MedLine Citation:
|
PMID: 23448676 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND AND PURPOSE: To evaluate the association between the use of azathioprine and risk of cancer in patients with non-thymoma myasthenia gravis (MG) in a nationwide setting. METHODS: Case-control study based on population-based registries. Cases were patients with MG with a first time diagnosis of cancer (except non-melanoma skin cancer) registered during 2000-2009, and controls were patients with MG with no history of cancer. Prior use of azathioprine in cases and controls was assessed through prescription records (1995-2009). We used unconditional logistic regression to calculate odds ratios (ORs) with 95% confidence intervals (CIs) for cancer associated with a high cumulative dose [≥ 1000 defined daily doses (DDD)] or long-term use (≥ 5 years) of azathioprine, compared with never use of the drug and adjusted for potential confounders. RESULTS: We identified 89 cases and 873 controls. The prevalence of ever use of azathioprine was similar among cases (39.3%) and controls (39.4%). We observed a slightly elevated OR for cancer overall associated with long-term use of azathioprine (1.22; 95% CI: 0.62-2.40, P = 0.56). The highest ORs were observed for use of 2000 DDD or more of azathioprine; however, these risk estimates were based on small numbers. CONCLUSIONS: Use of azathioprine in patients with non-thymoma MG may be associated with a slightly increased risk of cancer overall. Larger studies are necessary to address the risk of site-specific cancers. |
| | |
Authors:
|
E G Pedersen; A Pottegard; J Hallas; S Friis; K Hansen; P E H Jensen; D Gaist |
Related Documents
:
|
23510066 - Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of m... 23092516 - Antiblastic treatment, for solid tumors, during pregnancy: a crucial decision. 2833456 - Intraspinal opiates for treatment of intractable pain in the terminally ill cancer pati... 11709866 - Using focus group methods to develop multicultural cancer pain education materials. 23121766 - Using lithium as a neuroprotective agent in patients with cancer. 11393016 - Helplines. getting through. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-2-28 |
Journal Detail:
|
Title: European journal of neurology : the official journal of the European Federation of Neurological Societies Volume: - ISSN: 1468-1331 ISO Abbreviation: Eur. J. Neurol. Publication Date: 2013 Feb |
Date Detail:
|
Created Date: 2013-3-1 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9506311 Medline TA: Eur J Neurol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
© 2013 The Author(s) European Journal of Neurology © 2013 EFNS. |
Affiliation:
|
Department of Neurology, Faculty of Health Sciences, Institute of Clinical Research, Odense University Hospital, University of Southern Denmark (SDU), Odense, Denmark. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Revealing All: Misleading Self-Disclosure Rates in Laboratory-Based Online Research.
Next Document: Decision making about frozen supernumerary human embryos.